Spots Global Cancer Trial Database for CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)
Official Title: Immunotherapy With CD19ζ Gene-modified EBV-specific CTLs After Stem Cell Transplant in Children With High-risk Acute Lymphoblastic Leukaemia
Study ID: NCT01195480
Conditions
Study Description
Brief Summary: The aim of this clinical trial is to evaluate the feasibility, safety and biological effect of adoptive transfer of CD19ζ chimaeric receptor transduced donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTL) in patients with high-risk or relapsed B cell precursor ALL after allogeneic Haematopoietic Stem Cell Transplantation (HSCT).
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum, Essen, , Germany
Hospital for Children and Adolescents III, Goethe University, Frankfurt, , Germany
Medizinische Hochschule, Hannover, , Germany
University Children's Hospital, Münster, , Germany
Bristol Children's Hospital, Bristol, , United Kingdom
Great Ormond Street Hospital for Children, London, , United Kingdom
University College London Hospital, London, , United Kingdom
Contact Details
Name: Persis Amrolia, Professor
Affiliation: Great Ormond Street Hospital for Children NHS Foundation Trust
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
